VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Dadu on Reducing MTC-Related Diarrhea With CASAD

Ramona Dadu, MD
Published: Friday, Oct 31, 2014



Ramona Dadu, MD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders, MD Anderson Cancer Center, discusses the results of a pilot study that examined the efficacy of calcium aluminosilicate clay (CASAD) for reducing medullary thyroid cancer (MTC)- related diarrhea.

MTC-related diarrhea can reduce patients’ quality of life. While there are other drugs on the market that can be used to treat MTC-related diarrhea, they generally cause side effects. CASAD is all natural and used to treat diarrhea-related side effects in other cancer patients.

Dadu says 8 out of 9 patients discontinued the current anti-diarrhea medication they were taking after taking CASAD. Also, 7 out of 10 patients were evaluable for the primary endpoint and 4 out of 7 patients met the primary endpoint of reducing the severity of diarrhea.

The best results were seen in between 3 days and 21 days, Dadu says. Every patient on the study responded, with between a 9% and 99% reduction in their frequency of bowel movements. All patients also reported a significant improvement in their quality of life after taking CASAD, Dadu says.

<<< View more from the 2014 ATA Annual Meeting



Ramona Dadu, MD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders, MD Anderson Cancer Center, discusses the results of a pilot study that examined the efficacy of calcium aluminosilicate clay (CASAD) for reducing medullary thyroid cancer (MTC)- related diarrhea.

MTC-related diarrhea can reduce patients’ quality of life. While there are other drugs on the market that can be used to treat MTC-related diarrhea, they generally cause side effects. CASAD is all natural and used to treat diarrhea-related side effects in other cancer patients.

Dadu says 8 out of 9 patients discontinued the current anti-diarrhea medication they were taking after taking CASAD. Also, 7 out of 10 patients were evaluable for the primary endpoint and 4 out of 7 patients met the primary endpoint of reducing the severity of diarrhea.

The best results were seen in between 3 days and 21 days, Dadu says. Every patient on the study responded, with between a 9% and 99% reduction in their frequency of bowel movements. All patients also reported a significant improvement in their quality of life after taking CASAD, Dadu says.

<<< View more from the 2014 ATA Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x